EU-IN_VITRO_MEDICAL_DEVICES-ART_3_ANX_1
EU-IN_VITRO_MEDICAL_DEVICES-ART_3_ANX_1
In Vitro Diagnostic Medical Devices Directive - Hazardous Substances
EU. Hazardous Substances for Purposes of Article 3 & Annex I (Essential Requirements), Directive 98/79/EC on In Vitro Diagnostic Medical Devices, 7 December 1998
This list contains a non-exhaustive inventory of hazardous substances for purposes of essential requirements (Article 3 and Annex I) for general safety, design, manufacture and hazard communication of in vitro diagnostic medical devices. It is derived from: Table 3 of Annex VI to CLP, REACH Candidate List of SVHCs, and Directive 2000/54/EC's Annex III (Biological Agents list). Note that Regulation 2017/746/EU on in vitro diagnostic medical devices was published in the EU Official Journal on 5 May 2017. With few exceptions specified in Articles 112 and 113 of this Regulation, Directive 98/79/EC is repealed, and the rules pursuant to 2017/746/EU apply, from 26 May 2022.
Last updated 13 rujna 2024. Database contains 4821 unique substances/entries.
Filter the list
|
The oil obtained from the heat treatment of a polyethylene/polypropylene mixture with coal tar pitch or aromatic oils. It consists predominantly of benzene and its homologs boiling in a range of approximately 70°C to 120°C (158°F to 248°F).
|
309-745-9
|
100801-63-6
|
Carc. 1B; Muta. 1B |
||
|
600-130-3
|
100784-20-1
|
Repr. 1B |
|||
|
Solids formed during the coking of bituminous coal to produce crude bituminous coal high temperature tar. Composed primarily of coke and coal particles, highly aromatized compounds and mineral substances.
|
309-726-5
|
100684-51-3
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by treatment of petroleum slack wax with activated charcoal for the removal of trace polar constituents and impurities.
|
309-723-9
|
100684-49-9
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by treatment of solvent-dewaxed petroleum residual oils with bleaching earth for the removal of trace polar constituents and impurities.
|
309-711-3
|
100684-38-6
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by the treatment of solvent-dewaxed petroleum residual oils with activated charcoal for the removal of trace polar constituents and impurities.
|
309-710-8
|
100684-37-5
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by treatment of petrolatum with bleaching earth for the removal of traces of polar constituents and impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of greater than C25.
|
309-706-6
|
100684-33-1
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by solvent extraction of light vacuum petroleum gas oils treated with bleaching earth for removal of trace polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C13 through C30.
|
309-675-9
|
100684-05-7
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by solvent extraction of light vacuum petroleum gas oil treated with activated charcoal for the removal of trace polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C13 through C30.
|
309-674-3
|
100684-04-6
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained as a fraction from distillation of an extract recovered by solvent extraction of light paraffinic top petroleum distillates treated with bleaching earth to remove traces of polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C16 through C32.
|
309-673-8
|
100684-03-5
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained as a fraction from distillation of an extract recovered by solvent extraction of light paraffinic top petroleum distillate treated with activated charcoal to remove traces of polar constituents and impurities. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C16 through C32.
|
309-672-2
|
100684-02-4
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by the treatment of petroleum with bleaching earth for the removal of trace polar constituents and impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C16 through C36.
|
309-669-6
|
100683-99-6
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by the treatment of petroleum with activated charcoal for the removal of trace polar constituents and impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C16 through C36.
|
309-668-0
|
100683-98-5
|
Carc. 1B |
||
|
A complex combination of hydrocarbons obtained by the treatment of a petroleum oil fraction with activated charcoal for the removal of traces of polar constituents and impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C12 through C28.
|
309-667-5
|
100683-97-4
|
Carc. 1B |
||
|
233-195-8
|
10061-01-5
|
Flam. Liq. 3; Acute Tox. 3; Acute Tox. 4; Asp. Tox. 1; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2; Skin Sens. 1 |
|||
|
DM-8
|
405-880-3
|
100501-62-0
|
Skin Sens. 1 |
||
|
422-360-1
|
100491-29-0
|
Skin Sens. 1 |
|||
|
233-162-8
|
10049-04-4
|
Press. Gas; Ox. Gas 1; Acute Tox. 2; Skin Corr. 1B |
|||
|
233-162-8
|
10049-04-4
|
Acute Tox. 3; Skin Corr. 1B |
|||
|
233-154-4
|
10046-00-1
|
Expl. 1.1; Carc. 2; Acute Tox. 4; STOT RE 2; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
|||
|
233-140-8
|
10043-52-4
|
Eye Irrit. 2 |
|||
|
233-139-2
|
10043-35-3
|
Repr. 1B |
yes |
||
|
METHYLGELB
|
408-090-7
|
100418-33-5
|
Acute Tox. 4; Skin Sens. 1 |
||
|
233-118-8
|
10039-54-0
|
Met. Corr. 1; Carc. 2; Acute Tox. 4; STOT RE 2; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
|||
|
233-113-0
|
10035-10-6
|
Press. Gas; Skin Corr. 1A; STOT SE 3 |
|||
|
233-113-0
|
10035-10-6
|
Skin Corr. 1B; STOT SE 3 |
|||
|
233-109-9
|
10034-85-2
|
Skin Corr. 1B |
|||
|
233-109-9
|
10034-85-2
|
Press. Gas; Skin Corr. 1A |
|||
|
233-071-3
|
10028-18-9
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
-
|
10027-06-2
|
Acute Tox. 4; Skin Irrit. 2; Skin Sens. 1 |
|||
|
233-060-3
|
10026-13-8
|
Acute Tox. 2; Acute Tox. 4; STOT RE 2; Skin Corr. 1B |
|||
|
233-054-0
|
10026-04-7
|
Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
|||
|
233-051-4
|
10026-00-3
|
Acute Tox. 3; Skin Irrit. 2; Eye Dam. 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
233-050-9
|
10025-99-7
|
Acute Tox. 3; Skin Irrit. 2; Eye Dam. 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
233-047-2
|
10025-91-9
|
Skin Corr. 1B |
|||
|
233-046-7
|
10025-87-3
|
Acute Tox. 2; STOT RE 1; Acute Tox. 4; Skin Corr. 1A |
|||
|
233-042-5
|
10025-78-2
|
Flam. Liq. 1; Pyr. Liq. 1; Acute Tox. 4; Skin Corr. 1A |
|||
|
233-036-2
|
10025-67-9
|
Acute Tox. 3; Acute Tox. 4; Skin Corr. 1A |
|||
|
IVAX
|
401-920-9
|
100181-71-3
|
Skin Irrit. 2; Skin Sens. 1 |
||
|
233-002-7
|
10007-85-9
|
Eye Irrit. 2 |
|||
|
233-000-6
|
10004-44-1
|
Repr. 2; Acute Tox. 4; Eye Dam. 1; Skin Sens. 1 |
|||
|
CG 24-020; FERROCEN-SBF6
|
407-840-0
|
100011-37-8
|
Acute Tox. 4; Eye Dam. 1 |
||
|
LUPRAGEN VP 9159
|
401-660-6
|
1000-78-8
|
Skin Irrit. 2; Skin Sens. 1 |
||
|
202-905-8
|
100-97-0
|
Flam. Sol. 2; Skin Sens. 1 |
|||
|
202-873-5
|
100-63-0
|
Carc. 1B; Muta. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
|||
|
202-870-9
|
100-61-8
|
Acute Tox. 3; STOT RE 2 |
|||
|
202-866-7
|
100-57-2
|
Acute Tox. 3; STOT RE 1; Skin Corr. 1B |
|||
|
202-860-4
|
100-52-7
|
Acute Tox. 4 |
|||
|
202-859-9
|
100-51-6
|
Acute Tox. 4 |
|||
|
202-855-7
|
100-47-0
|
Acute Tox. 4 |
|||
|
202-854-1
|
100-46-9
|
Acute Tox. 4; Skin Corr. 1B |
|||
|
202-853-6
|
100-44-7
|
Carc. 1B; Acute Tox. 3; Acute Tox. 4; STOT RE 2; STOT SE 3; Skin Irrit. 2; Eye Dam. 1 |
|||
|
202-851-5
|
100-42-5
|
Flam. Liq. 3; Repr. 2; Acute Tox. 4; STOT RE 1; Skin Irrit. 2; Eye Irrit. 2 |
|||
|
202-849-4
|
100-41-4
|
Flam. Liq. 2; Acute Tox. 4; STOT RE 2; Asp. Tox. 1 |
|||
|
202-848-9
|
100-40-3
|
Carc. 2 |
|||
|
202-847-3
|
100-39-0
|
Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
|||
|
202-845-2
|
100-37-8
|
Flam. Liq. 3; Acute Tox. 4; Skin Corr. 1B |
|||
|
202-833-7
|
100-25-4
|
Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
|||
|
202-831-6
|
100-22-1
|
Acute Tox. 4 |
|||
|
202-811-7
|
100-02-7
|
Acute Tox. 4; STOT RE 2 |
|||
|
202-810-1
|
100-01-6
|
Acute Tox. 3; STOT RE 2 |
|||
|
202-809-6
|
100-00-5
|
Carc. 2; Muta. 2; Acute Tox. 3; STOT RE 2 |
|||
|
936-037-2
|
-
|
yes |
|||
|
425-240-7
|
-
|
Eye Dam. 1 |
|||
|
show/hide
|
-
|
-
|
Carc. 1A; Acute Tox. 4; Skin Sens. 1 |
||
|
-
|
-
|
B Bacteria and similar species |
|||
|
-
|
-
|
B Bacteria and similar species |
|||
|
-
|
-
|
B Bacteria and similar species |
|||
|
-
|
-
|
B Bacteria and similar species |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
P Parasites |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
B Bacteria and similar species |
|||
|
-
|
-
|
B Bacteria and similar species |
|||
|
-
|
-
|
B Bacteria and similar species |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
|||
|
show/hide
Titanate(4-), oxobis[phosphato(3-)]-, barium (1:2), uranium-doped
EC / List no:
309-550-9
| CAS no:
100403-10-9
Sodium uranyl triacetate, of uranium depleted in uranium-235
EC / List no:
241-714-4
| CAS no:
17712-38-8
Nickel uranyl tetraacetate, of uranium depleted in uranium-235
EC / List no:
275-994-4
| CAS no:
71767-12-9
Dipotassium uranyl bis(sulphate), of uranium depleted in uranium-235
EC / List no:
262-284-4
| CAS no:
60542-74-7
Tetraammonium uranyl tricarbonate, of uranium depleted in uranium-235
EC / List no:
241-988-5
| CAS no:
18077-77-5
Calcines, uranium ore-conc.
Calcined precipitates of ammonium, magnesium or sodium uranates obtained from natural uranium ores.
EC / List no:
297-819-0
| CAS no:
93763-02-1
Disodium heptaoxodiuranate, of uranium depleted in uranium-235
EC / List no:
237-286-3
| CAS no:
13721-34-1
|
-
|
-
|
Acute Tox. 2; STOT RE 2 |
||
|
-
|
-
|
P Parasites |
|||
|
-
|
-
|
P Parasites |
|||
|
-
|
-
|
P Parasites |
|||
|
-
|
-
|
P Parasites |
|||
|
RED JB 747
|
418-220-4
|
-
|
Skin Sens. 1 |
||
|
TURQUOISE 10 40 518
|
411-430-7
|
-
|
Eye Dam. 1; Skin Sens. 1 |
||
|
423-100-1
|
-
|
Eye Dam. 1 |
|||
|
BLUE TZ 4312
|
423-770-3
|
-
|
Eye Dam. 1 |
||
|
show/hide
|
799-976-5
|
-
|
yes |
||
|
-
|
-
|
Acute Tox. 3 |
|||
|
-
|
-
|
Acute Tox. 3 |
|||
|
-
|
-
|
Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
|||
|
-
|
-
|
Acute Tox. 2; Acute Tox. 1 |
|||
|
-
|
-
|
Acute Tox. 2; Acute Tox. 1 |
|||
|
-
|
-
|
P Parasites |
|||